Abstract: A silicon-and germanium-based molecular sieve has a framework chemical composition as represented by the formula “SiO2.1/nGeO2”. The silicon/germanium molar ratio is 0.1n30. The molecular sieve has a unique X-ray diffraction pattern. It can be used in adsorptive separation, ion exchange, and catalytic conversion of organic compounds.

Abstract: The present disclosure concerns recombinant yeast host cells having a first genetic modification to express a heterologous polypeptide or to over-express a native polypeptide. The recombinant yeast host cells also have a second genetic modification to at least partially mitigate the reduction in growth rate resulting from the expression of the heterologous polypeptide or the over-expression of the native polypeptide. The second genetic modification can be, for example, to favor the secretion of the heterologous or native polypeptide.

Abstract: The present application discloses a VICTS antenna based on an RGW structure, comprising an RGW feeding layer and a radiation layer arranged in sequence, wherein the RGW feeding layer comprises an RGW power splitter and a dielectric substrate for slow wave design, and the RGW power splitter is arranged under the dielectric substrate, wherein a power splitting network cover plate is arranged between the RGW feeding layer and the radiation layer, wherein the RGW power splitter comprises a feeding network and a waveguide feeding port, through which signals are input into the feeding network; the radiation layer is composed of a plurality of CTS arrays. During signal transmission, the signals are input into the feeding network through the waveguide port, and then the signals are fed into each CTS array by the feeding network; the radiation layer is configured to rotate.

Abstract: Described is a nucleic acid ligand, a mixture thereof, and the use thereof. The mixture contains two or more nucleic acid polymerase substrate analogs. The nucleic acid polymerase substrate analog is a single nucleic acid molecule or nucleic acid molecule analog which forms complementary pairing within a molecule, or a single or two nucleic acid molecules or nucleic acid molecule analogs which form complementary pairing between molecules; and a structure formed thereby has the characteristics of a nucleic acid polymerase substrate. The nucleic acid polymerase substrate analog is suitable for all polymerases and can be widely used in the field of nucleic acid amplification. The 3? end of the nucleic acid ligand has a modification which inhibits the extension thereof.

Abstract: Provided is a method for preparing bencaosome comprising the steps of: mixing one or more lipid components with any one or more of the following: nucleic acid, compound and mancromolecules, and treating the obtained mixture by heating. Also provided is a method for extracting decoctosome from plants comprising the steps of: preparing an extract of the plant with a solvent; performing differential centrifugation to the extract; resuspending the precipitates with an aqueous solution to provide the decoctosome.

Abstract: The present application relates to extracting a plurality of compounds from a traditional Chinese medicine, or synthesizing a compound capable of promoting nucleic acid delivery, and utilizing the extracted compound, or a plurality of combinations to promote absorption and entry of a nucleic acid such as sRNA into a target cell, and to facilitate the entry of a nucleic acid into a target site in a subject in need thereof

Abstract: The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restricted manner, using dendritic cells as the antigen-presenting cells and DOTAP to deliver the Sp17 protein to the dendritic cells. A combination of HLA-matched and mismatched antibody-enriched fresh myeloma tumor cells and myeloma cell lines were used as targets for the recombinant protein-propagated CTL. The findings of target cell lysis suggest that the Sp17 protein produced by Sp17+ tumor cells are processed and presented in vivo and that the CTL epitopes are presented in association with HLA class I molecules in a concentration and configuration recognized by recombinant protein-propagated CTL.

Abstract: The present invention relates to methods for diagnosing cancer in a subject The method involves obtaining a biological sample from a subject and measuring SPAN-Xb expression level in the biological sample. The SPAN-Xb expression level in the biological sample is compared to the SPAN-Xb expression level in a control sample from a subject devoid of cancer, where a greater SPAN-Xb expression level in the biological sample compared to the SPAN-Xb expression level in the control sample is indicative of the subject having cancer. Methods for monitoring progression/regression of cancer in a subject are also disclosed. The present invention also relates to methods of treating a subject with cancer. The method involves administering to the subject a therapeutically effective amount of an agent capable of eliciting an immunological response against SPAN-Xb protein or specifically recognizing a SPAN-Xb protein, under conditions effective to-treat a cancer characterized by cells expressing SPAN-Xb.

Abstract: The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restricted manner, using dendritic cells as the antigen-presenting cells and DOTAP to deliver the Sp17 protein to the dendritic cells. A combination of HLA-matched and mismatched antibody-enriched fresh myeloma tumor cells and myeloma cell lines were used as targets for the recombinant protein-propagated CTL. The findings of target cell lysis suggest that the Sp17 protein produced by Sp17+ tumor cells are processed and presented in vivo and that the CTL epitopes are presented in association with HLA class I molecules in a concentration and configuration recognized by recombinant protein-propagated CTL.